Acute Non-Bulky Non-Lymphomatous ATLL: Consolidation After Response to First-Line Therapy

This protocol addresses acute adult T-cell leukaemia-lymphoma in patients without bulky lesions and not of lymphoma-type, who have achieved a chemosensitive response to first-line treatment and are now candidates for the consolidation phase.

Preceding treatment line & response criterion

First-line therapy consists of high-dose zidovudine combined with high-dose interferon-α, together with CNS prophylaxis and antimicrobial prophylaxis for all patients with acute-type ATLL. Consolidation is indicated specifically for patients who demonstrate chemosensitive disease responding to that first-line regimen; achieving this response is the criterion that brings a patient to this protocol.

Clinical Scenario

The patient has acute ATLL without bulky lesions, does not have the lymphoma subtype, and has responded to first-line antiviral-based therapy. The consolidation phase is now the defined next step.

Consolidation Approach

For chemosensitive patients, consolidation centres on allogeneic haematopoietic stem-cell transplantation, with a specific adaptation to the conditioning regimen to address a virus-related risk. For responding patients who are not eligible for transplantation, antiviral-based maintenance therapy is the established alternative, with further substitution options available if that approach becomes unsuitable. The complete eligibility criteria, full regimen details, and decision algorithm are available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.annonc.2025.01.023

High-dose zidovudine-IFN-α can be recommended as first-line therapy for patients with acute, non-bulky, non-lymphomatous ATLL whenever feasible, particularly for those who are unsuitable for intensive ChT or allo-HSCT [III, B; not EMA or FDA approved].
Chemosensitive patients can proceed to allo-HSCT [III, B].
An antiretroviral agent can be added to the conditioning regimen to prevent HTLV-1 neoinfection of donor cells [III, B].
Responding patients who are ineligible for allo-HSCT may receive maintenance therapy with zidovudine-IFN-α with or without arsenic trioxide [III, C; not EMA or FDA approved].
If zidovudine-IFN-α is poorly tolerated or there is no longer a response, oral low-dose etoposide may be considered as monotherapy or as part of a regimen [III, C].

View source ↗